PAQ Therapeutics

PAQ Therapeutics is a biotechnology company pioneering a new approach to restoring health and curing disease through autophagy, the body’s most versatile mechanism for natural cellular degradation.

PAQ uses its ATTEC (autophagosome-tethering compound) technology, where small molecules can selectively enhance the degradation of disease causing entities. PAQ’s research advances are driving an important new class of degradation therapies with the potential to target a range of substrates including proteins, aggregates, lipids, organelles and pathogens.

The company’s initial focus is on a genetic neurodegenerative disorder with no current treatment options for patients. PAQ plans to expand the ATTEC platform to target additional disease-causing protein and non-protein targets.

PAQ was founded in 2020 by Boxun Lu, Huaixiang Hao, and Nan Ji, and raised US $30 million is a Series A round in July 2021.

Subscribe for alerts on new companies featured on Startups.Bio

Archon Biosciences
Archon Biosciences is a biotech company pioneering computationally designed 'Antibody Cages' to unlock powerful therapeutic targets beyond the reach of existing modalities. Archon directly applies generative protein design to rapidly …
Cytospire Therapeutics
Founded in 2023, Cytospire Therapeutics is developing a portfolio of next-generation immune cell engagers for treating cancer. The company's multispecific antibodies are designed to harness and direct the power of …
This Week in Biotech Venture Capital
The biotech sector continues to see a strong flow of new venture capital deals, with a flurry of new announcements this week. We saw a diverse set of companies—ranging from …
THRONCAT
THRONCAT is a new startup that aims to transform the field of protein analysis and mRNA therapeutics safety. THRONCAT began with a mission to make protein analysis more accessible and …

View all recently featured startups

Tags: